Skip to main content

Novo Nordisk's Wegovy wins EU backing for reducing heart risks

Novo Nordisk's Wegovy has received backing from the EU's medical regulator to expand the weight loss drug's use to reducing the rise of serious heart events.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.